Vaxcyte, Inc. - Common Stock (NQ:PCVX)

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

October 09, 2026

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Performance

52-Week Range 24.4% below 52-week high

68.62

42.4052W Low 90.7552W High

1 Week 0.4% below 1-week high

61.141W Low 68.921W High

Vaxcyte, Inc. - Common Stock (PCVX) traded between $42.40 and $90.75 over the past 52 weeks and last traded at $68.62, 24.4% below its 52-week high. Over the past week it ranged between $61.14 and $68.92.

Past 12 Months

+10.8%

-2.9%

+15.0%

+26.5%

+47.7%

+50.3%

1W +$6.70

1M -$2.03

3M +$8.97

6M +$14.37

YTD +$22.16

1Y +$22.96

PCVX was +50.3% over the past year, +26.5% over six months, +47.7% year to date, +10.8% in the last week.

12 Months vs Market

PCVX

+50.3%

DIA

+9.4%

SPY

+11.2%

QQQ

+11.1%

IWM

+15.9%

Over the past 12 months PCVX returned +50.3% versus DIA (Dow) +9.4%, SPY (S&P 500) +11.2%, QQQ (Nasdaq 100) +11.1% and IWM (Russell 2000) +15.9%.

Volume & Liquidity 0.00× 3-mo avg

Today 6 3-mo avg 2.2M

1.6M

2.1M

2.2M

1.8M

YTD

1.6M

PCVX most recently traded 6 shares against a 3-month average daily volume of 2.2M.

More News

October 06, 2026

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial ↗

October 05, 2026

Via MarketBeat

October 05, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Keep an eye on the top gainers and losers in Monday's session. ↗

October 05, 2026

Via Chartmill

Monday's session: gap up and gap down stocks ↗

October 05, 2026

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

October 05, 2026

Via Chartmill

October 05, 2026

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 04, 2026

Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing ↗

September 08, 2026

A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know ↗

September 08, 2026

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm ↗

September 08, 2026

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

September 03, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

August 27, 2026

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

August 05, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

July 08, 2026

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

June 02, 2026

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026